The UK's medicines regulator launched a four-year Women's Health Programme on 16 November 2026 to address evidence gaps about how medicines and medical devices work for women. The Medicines and Healthcare products Regulatory Agency (MHRA) says the programme will improve clinical research, product assessment and the information patients receive. It is a regulatory programme, not a new law requiring every trial to recruit a fixed number of women.

The scale of the problem is unusually clear. In an analysis of 4,616 UK clinical-trial applications from 2019 to 2023, the MHRA found pregnant women were represented in 1.1% of trials and breastfeeding women in 0.6%. Those figures describe the share of trials involving those groups, not the percentage of all participants who were pregnant or breastfeeding.

Key facts

  • Launch: The MHRA published the Women's Health Programme 2026-2030 on 16 November 2026.
  • Evidence gap: Its review of 4,616 trial applications found pregnant women represented in 1.1% of trials and breastfeeding women in 0.6%.
  • Approach: The programme covers sex-specific evidence before authorisation, monitoring after products reach patients, and clearer information about risks and benefits.
  • Next test: The Health Research Authority (HRA) plans a larger voluntary trial of inclusion and diversity plans from early 2027, following a seven-study pilot.

What changes in the regulatory process

The MHRA wants researchers and manufacturers to consider differences between women and men throughout a product's life. Its programme proposes more consistent submission and assessment of sex-disaggregated information, better use of real-world data, and clearer communication of differences in safety or effectiveness when those differences are supported by evidence.

For pregnant and breastfeeding patients, the problem is especially consequential. Exclusion from development studies can leave clinicians relying on limited evidence when deciding whether treatment is appropriate. The MHRA intends to pilot approaches that combine clinical evidence with post-market information and other relevant data. It also plans to explore ways of improving product leaflets and risk communication. None of that means an individual medicine has been declared safe in pregnancy today.

The programme is broader than reproductive health. It covers medical devices and digital technologies, including products in the growing women's-health technology sector, and conditions that can affect women differently or disproportionately. Its stated aims include identifying unmet needs, supporting suitable new products and maintaining existing safety and effectiveness standards.

Unlike a conventional approval announcement, this initiative does not immediately authorise a new therapy or change an individual patient's prescription. It sets work for the regulator and its partners through 2030. Its impact will depend on whether product developers generate usable evidence and whether that evidence eventually changes assessments, labelling and clinical decisions.

A smaller pilot shows both the potential and the difficulty

A related HRA-MHRA project offers a test of implementation. The HRA reported on 2 November that seven studies volunteered for an inclusion and diversity planning pilot in 2025: five backed by commercial sponsors and two by non-commercial sponsors. Five were phase III medicinal-product trials and two involved medical devices.

Commercial sponsors generally said the plans helped them think about representation more systematically. Feedback from research ethics committee members was mixed, partly because an additional document could duplicate information already reviewed. Researchers also identified difficulty obtaining reliable UK-specific population data. These are findings from seven volunteer studies, not evidence that the approach has already improved health outcomes.

The HRA now plans to invite more researchers to submit plans from early 2027 and collect feedback over 12 months. Participation at this stage is voluntary, and only a small number of ethics committees will initially be involved. The expansion is separate from the MHRA's newly published women's-health programme, although the agencies say their work is aligned.

The bigger question is whether a system built around trials and licensing can fill gaps without delaying access to useful treatments. The MHRA's proposed response combines earlier scrutiny of research populations with greater use of evidence gathered after marketing. That may give regulators more information, but it does not replace the need to judge each product's risks and benefits.

The next visible milestones are the MHRA's December programme webinar and the HRA's proposed 2027 implementation phase. For patients, the meaningful test will be whether published evidence and product information become more specific, rather than simply whether another policy document has appeared.